New perspectives in pulmonary arterial hypertension treatment: 2009 European recommendations

New perspectives in pulmonary arterial hypertension treatment: 2009 European recommendations

Pulmonary arterial hypertension (PAH) is one of the most severe cardiovascular disorders. It is characterised by progressing clinical course, right ventricular failure development, and very poor prognosis. In September 2009, the European Society of Cardiology and the European Respiratory Society rel...

Full description

Bibliographic Details
Main Authors:	T. V. Martynyuk, S. N. Nakonechnikov, I. E. Chazova
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2010-04-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	легочная артериальная гипертензия антагонисты кальция антикоагулянты диуретики антагонисты рецепторов эндотелина простаноиды ингибиторы фосфодиэстеразы типа 5
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/2048

Similar Items

Rapidly progressive idiopathic pulmonary hypertension in a child
by: D. I. Sadykova, et al.
Published: (2016-03-01)

OPTIMIZATION OF SPECIFIC THERAPY FOR PULMONARY ARTERIAL HYPERTENSION: THE POSSIBILITIES OF USING ENDOTHELIN RECEPTOR ANTAGONISTS
by: T. V. Martynyuk, et al.
Published: (2017-06-01)

EXPERIENCE OF USING THE NONSELECTIVE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
by: M. A. Simakova, et al.
Published: (2018-04-01)

OPPORTUNITIES FOR OPTIMIZATION OF DRUG THERAPY BY ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION AND ATRIAL SEPTOSTOMY
by: V. V. Gramovich, et al.
Published: (2018-12-01)

MACITENTAN: THE EVOLUTION OF THE CLASS ENDOTHELIN RECEPTOR ANTAGONISTS TO IMPROVE EFFICACY AND SAFETY OF PAH TREATMENT
by: T. V. Martynuk, et al.
Published: (2013-06-01)

Portopulmonary hypertension in a child
by: D. I. Sadykova, et al.
Published: (2016-11-01)

CLINICAL CASE OF COMBINATION THERAPY INCLUDING AMBRIZENTAN IN THE PATIENT WITH SEVERE IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
by: G. A. Movsisyan, et al.
Published: (2017-06-01)

Controlled arterial hypertension and adverse event free survival rate in heart recipients
by: A. О. Shevchenko, et al.
Published: (2018-08-01)

NEW OPPORTUNITIES PATHOGENETIC THERAPY OF PULMONARY ARTERIAL HYPERTENSION
by: T. V. Martynuk, et al.
Published: (2013-03-01)

Lercanidipine in arterial hypertension
by: C. Borghi
Published: (1970-01-01)

AMBRISENTAN: THE POSSIBILITY OF THE TREATMENT FOR PULMONARY ARTERIAL HYPERTENSION WITH THE SELECTIVE BLOCKADE OF THE ENDOTHELIN SYSTEM
by: T. V. Martynuk, et al.
Published: (2014-03-01)

THE EFFICACY OF SILDENAFIL THERAPY IN PATIENTS WITH PULMONARY HYPERTENSION OF DIFFERENT ETIOLOGY: INFLUENCE ON THE CLINICAL, FUNCTIONAL, HEMODYNAMIC STATUS, STRUCTURE AND FUNCTION OF THE RIGHT AND LEFT HEART, RIGHT VENTRICULAR-ARTERIAL COUPLING
by: T. V. Martynyuk, et al.
Published: (2017-03-01)

Modern pharmaceutical treatment of pulmonary arterial hypertension
by: T. A. Batyraliev, et al.
Published: (2008-12-01)

LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION
by: O. D. Ostroumova, et al.
Published: (2015-09-01)

CLINICAL CASE OF SUCCESSFUL 10-YEAR AMBRIZENTAN TREATMENT OF THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
by: T. V. Martynyuk, et al.
Published: (2015-12-01)

Choosing therapeutic tactics in pregnant women with chronic arterial hypertension: the priorities
by: N. G. Pivonova, et al.
Published: (2009-08-01)

ORAL ANTICOAGULANTS IN PATIENTS WITH DIFFERENT FORMS OF PULMONARY ARTERIAL HYPERTENSION, ASPECTS OF THE PROBLEM
by: S. Ye. Gratsianskaya, et al.
Published: (2017-12-01)

ВЛИЯНИЕ КОМБИНИРОВАННОЙ ТЕРАПИИ НА ЦЕНТРАЛЬНОЕ АРТЕРИАЛЬНОЕ ДАВЛЕНИЕ И АРТЕРИАЛЬНУЮ РИГИДНОСТЬ
Published: (2016-12-01)

Cardiometabolic properties of telmisartan: new perspectives for use
by: O. M. Drapkina, et al.
Published: (2015-12-01)

Combination of dihydropyridine and non-dihydropyridine calcium antagonists in patients with arterial hypertension and coronary heart disease: efficacy and safety
by: B. G. Iskanderov, et al.
Published: (2005-12-01)

APPLICATION OF PHOSPHODIESTERASE TYPE 5 INHIBITORS SILDENAFIL IN PATIENTS WITH PULMONARY HYPERTENSION
by: T. V. Martynyuk, et al.
Published: (2015-06-01)

Endothelial dysfunction in arterial hypertension: focus on the combination of trandolapril and verapamil
by: V. I. Makolkin
Published: (2010-08-01)

Antagonisty kal'tsiya v lechenii arterial'noy gipertonii (issledovanie ETNA)
by: I E Chazova, et al.
Published: (2005-03-01)

Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
by: E. A. Rezukhina, et al.
Published: (2021-09-01)

Covremennye predstavleniya ob ideal'noy kombinatsii antigipertenzivnykh preparatov dlya profilaktiki insul'ta
by: Ol'ga Dmitrievna Ostroumova, et al.
Published: (2013-09-01)

TACTICS FEATURES OF CONDUCTING AND CHOOSING SPECIFIC THERAPY FOR ADULT PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONGENITAL HEART DISEASE
by: O. A. Arkhipova, et al.
Published: (2018-03-01)

Endothelial functional activity and circadian blood pressure dynamics in hypertensive patients treated with angiotensin receptor antagonists
by: N. G. Poteshkina, et al.
Published: (2011-10-01)

Calcium antagonists in patients with high cardiovascular risk
by: A. A. Garganeeva
Published: (2009-08-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

CALCIUM ANTAGONISTS IN CLINICAL PRACTICE: FOCUS ON METABOLIC AND VASCULAR EFFECTS
by: D. V. Nebieridze
Published: (2015-12-01)

CLINICAL AND PHARMACOKINETIC EQUIVALENCE OF ORIGINAL AND GENERIC AMLODIPINE IN PATIENTS WITH MILD-TO-MODERATE ARTERIAL HYPERTENSION
by: N. A. Belolipetskiy, et al.
Published: (2015-12-01)

AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND CALCIUM ANTAGONIST COMBINATION IN PHARMACOTHERAPY OF ARTERIAL HYPERTENSION
by: L. L. Kirichenko, et al.
Published: (2014-02-01)

FREE-RADICAL OXIDATION ACTIVITY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITHOUT Q WAVE TREATED WITH EPROSARTAN OR ENALAPRIL ADDITIONALLY TO THE BASIC THERAPY
by: O. G. Zaylobidinov, et al.
Published: (2016-01-01)

TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01)

FIXED COMBINATION OF THE CALCIUM CHANNEL BLOCKER LERCANIDIPINE AND ANGIOTENSIN CONVERTING ENZYME INHIBITOR ENALAPRIL: POSSIBILITY OF USAGE
by: O. D. Ostroumova, et al.
Published: (2015-09-01)

Calcium antagonist effectiveness and tolerability in hypertensive men and women
by: A. E. Bragina, et al.
Published: (2006-08-01)

VESSEL WALL STIFFNESS IN ARTERIAL HYPERTENSION AND OPPORTUNITIES FOR ITS MODULATION
by: L. L. Kirichenko, et al.
Published: (2016-12-01)

CLINICAL CASE: COMBINATION THERAPY WITH BOSENTAN AND SILDENAFIL IN THE TREATMENT OF IDIOPATHIC PULMONARY HYPERTENSION
by: V. V. Bystrov, et al.
Published: (2014-12-01)

Clinical pharmacology of the combination of ACE inhibitors and calcium antagonists: benefits of the perindopril arginine and amlodipine combination
by: M. V. Leonova
Published: (1970-01-01)

CASE REPORT ON THE SUCCESSFUL USE OF A NEW SELECTIVE PROSTACYCLIN IP RECEPTOR AGONIST, SELEXIPAG, IN A PATIENT WITH IDIOPATHIC PULMONARY HYPERTENSION
by: Z. S. Valieva, et al.
Published: (2019-12-01)